Back to results
US 2007/0179133 A1Published application
Compositions useful as inhibitors of protein kinases
AssigneeVertex Pharmaceuticals Incorporated
InventorsDavid Bebbington, Hayley Binch, Jean-Damien Charrier, Simon Everitt, Julian Golec, David Kay, Ronald Knegtel, Andrew Miller, Francoise Pierard
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Claims34
A compound of formula Ia or Ib:
- or a pharmaceutically acceptable derivative thereof, wherein:
- R2 is —R, oxo, halogen, —CN, —NO2, —CO2R, —Ar, -T-Ar, or -T-R;
- R2′ is R, or
- R2 and R2′ are taken together to form a optionally substituted 5-7 membered, partially unsaturated or fully unsaturated ring having zero to two ring heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
- each substitutable ring nitrogen of the ring formed by R2 and R2′ is optionally substituted;
- each occurrence of R is independently hydrogen, an optionally substituted C1-6 aliphatic group, or Ar;
- Z1 is nitrogen or CRx;
- Rx is —R, halogen, —N(R)2, —NO2, —CN, —CO2R, —OR, or —SR;
- wherein
- two R bound to the same nitrogen atom may be taken together with that nitrogen atom to form a five or six membered heterocyclic or heteroaryl ring having one to two additional heteratom's independently selected from oxygen, nitrogen, or sulfur;
- Z2 is nitrogen or CRy, provided that Z1 and Z2 are not simultaneously nitrogen;
- Ry is —R1, —CN, halogen, —NO2, —Ar, -T-Ar, or -T-R, or
- Rx and Ry are taken together to form an optionally substituted 5-7 membered partially unsaturated or fully unsaturated ring having zero to two heteroatoms independently selected from oxygen, sulfur, or nitrogen, wherein:
- each substitutable ring nitrogen of the ring formed by Rx and Ry is optionally substituted;
- R1 is hydrogen or an optionally substituted C1-6 aliphatic group;
- each Ar is independently an optionally substituted 3-6 membered heterocyclic ring having one or two heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- or a 5 or 6 membered aryl ring having zero to three heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein:
- Ar is optionally fused to a five or six membered partially unsaturated, or fully unsaturated ring having zero to two heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- T is a C1-4 alkylidene chain wherein one methylene unit of T is optionally replaced by —O—, —S—, —C(O)—, —CO2—, —NR—, —NRC(O)—, —NRC(O)NR—, —C(O)C(O)—, —OC(O)NR—, —NRCO2—, —SO2NR—, —NRSO2—, or —NRSO2NR—;
- Q is —N(R′)—, —S—, —O—, —C(R′)2—, or a valence bond, provided that Q is other than a valence bond when Ht is a triazole ring;
- wherein
- each R′ is independently hydrogen or C1-6 aliphatic;
- and
- Ring D is a 5 or 6 membered optionally substituted monocyclic aryl ring having zero to two heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- or an eight to ten membered partially unsaturated or fully unsaturated bicyclic ring having zero to four heteroatoms independently selected from nitrogen, oxygen, or sulfur.
22 more elements
Dependencies are inferred from the claim text.